According to the U.S. Food and Drug Administration (FDA), a combination product is defined as, Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products. The growing prevalence of chronic diseases among elderly population, creates an inevitable need for effective therapeutic solutions. In light of such need, pharmaceutical and medical device industries now offer Combination products. Growing number of elderly population, increasing healthcare expenditures along with the increasing popularity of point of care treatments, are some of the vital factors that promote the growth of the global Drug-device combination products market. Additionally, active interventions from the NGO and government organizations, along with the increasing demand for minimally invasive surgeries, would eventually propel the market growth during the forecast period. However, high cost of drugs, rising incidences of chronic disease, adverse side effects associated with products and growing technical challenges to deliver drugs would act as a major restraint to the market. Biological therapies and gene therapies are potential target areas for the global drug-device combination products market. The market is supported by newly developed sciences such as nanotechnology, information technology, polymer science, proteomics and genomics.